• 1
    Jemal A,Siegel R,Ward E,Murray T,Xu J,Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 4366.
  • 2
    Parkin DM,Bray F,Ferlay J,Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74108.
  • 3
    Selby JV,Friedman GD,Quesenberry CP,Jr,Weiss NS. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med 1992; 326: 6537.
  • 4
    Loeve F,van Ballegooijen M,Boer R,Kuipers EJ,Habbema JD. Colorectal cancer risk in adenoma patients: a nation-wide study. Int J Cancer 2004; 111: 14751.
  • 5
    Regueiro CR. AGA Future Trends Committee report: Colorectal cancer: a qualitative review of emerging screening and diagnostic technologies. Gastroenterology 2005; 129: 1083103.
  • 6
    Cooper GS. Colonoscopy: a tarnished gold standard? Gastroenterology 2007; 132: 258890.
  • 7
    Soetikno R,Friedland S,Kaltenbach T,Chayama K,Tanaka S. Nonpolypoid (flat and depressed) colorectal neoplasms. Gastroenterology 2006; 130: 56676.
  • 8
    Ross AS,Waxman I. Flat and depressed neoplasms of the colon in Western populations. Am J Gastroenterol 2006; 101: 17280.
    Direct Link:
  • 9
    Hurlstone DP,Cross SS,Slater R,Sanders DS,Brown S. Detecting diminutive colorectal lesions at colonoscopy: a randomised controlled trial of pan-colonic versus targeted chromoscopy. Gut 2004; 53: 37680.
  • 10
    Kiesslich R,von Bergh M,Hahn M,Hermann G,Jung M. Chromoendoscopy with indigocarmine improves the detection of adenomatous and nonadenomatous lesions in the colon. Endoscopy 2001; 33: 10016.
  • 11
    Kiesslich R,Jung M,DiSario JA,Galle PR,Neurath MF. Perspectives of chromo and magnifying endoscopy: how, how much, when, and whom should we stain? J Clin Gastroenterol 2004; 38: 713.
  • 12
    Taniyama Y,Suzuki T,Mikami Y,Moriya T,Satomi S,Sasano H. Systemic distribution of somatostatin receptor subtypes in human: an immunohistochemical study. Endocr J 2005; 52: 60511.
  • 13
    Krempels K,Hunyady B,O'Carroll AM,Mezey E. Distribution of somatostatin receptor messenger RNAs in the rat gastrointestinal tract. Gastroenterology 1997; 112: 194860.
  • 14
    Vuaroqueaux V,Dutour A,Bourhim N,Ouafik L,Monges G,Briard N,Sauze N,Oliver C,Grino M. Increased expression of the mRNA encoding the somatostatin receptor subtype five in human colorectal adenocarcinoma. J Mol Endocrinol 2000; 24: 397408.
  • 15
    Schaer JC,Waser B,Mengod G,Reubi JC. Somatostatin receptor subtypes sst1, sst2, sst3 and sst5 expression in human pituitary, gastroentero-pancreatic and mammary tumors: comparison of mRNA analysis with receptor autoradiography. Int J Cancer 1997; 70: 5307.
  • 16
    Warhurst G,Higgs NB,Fakhoury H,Warhurst AC,Garde J,Coy DH. Somatostatin receptor subtype 2 mediates somatostatin inhibition of ion secretion in rat distal colon. Gastroenterology 1996; 111: 32533.
  • 17
    McKeen ES,Feniuk W,Humphrey PP. Mediation by SRIF1 receptors of the contractile action of somatostatin in rat isolated distal colon; studies using some novel SRIF analogues. Br J Pharmacol 1994; 113: 62834.
  • 18
    Cooke HJ,Wang YZ,Wray D,O'Dorisio MS,Woltering EA,Coy DH,Murphy WA,Christofi FL,Gosh P,O'Dorisio TM. A multi-tyrosinated sst1/2 receptor preferring somatostatin agonist inhibits reflex and immune-mediated secretion in the guinea pig colon. Regul Pept 2003; 114: 5160.
  • 19
    Reubi JC,Schaer JC,Waser B,Wenger S,Heppeler A,Schmitt JS,Macke HR. Affinity profiles for human somatostatin receptor subtypes SST1–SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000; 27: 27382.
  • 20
    Schillaci O,Spanu A,Scopinaro F,Falchi A,Corleto V,Danieli R,Marongiu P,Pisu N,Madeddu G,Delle Fave G,Madeddu G. Somatostatin receptor scintigraphy with 111In-pentetreotide in non-functioning gastroenteropancreatic neuroendocrine tumors. Int J Oncol 2003; 23: 168795.
  • 21
    Chiti A,Fanti S,Savelli G,Romeo A,Bellanova B,Rodari M,van Graafeiland BJ,Monetti N,Bombardieri E. Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours. Eur J Nucl Med 1998; 25: 13961403.
  • 22
    Laws SA,Gough AC,Evans AA,Bains MA,Primrose JN. Somatostatin receptor subtype mRNA expression in human colorectal cancer and normal colonic mucosae. Br J Cancer 1997; 75: 3606.
  • 23
    Vuaroqueaux V,Dutour A,Briard N,Monges G,Grino M,Oliver C,Ouafik L. No loss of sst receptors gene expression in advanced stages of colorectal cancer. Eur J Endocrinol 1999; 140: 3626.
  • 24
    Radulovic SS,Milovanovic SR,Cai RZ,Schally AV. The binding of bombesin and somatostatin and their analogs to human colon cancers. Proc Soc Exp Biol Med 1992; 200: 394401.
  • 25
    Iftikhar SY,Thomas WM,Rooney PS,Morris DL. Somatostatin receptors in human colorectal cancer. Eur J Surg Oncol 1992; 18: 2730.
  • 26
    Raggi CC,Calabrò A,Renzi D,Briganti V,Cianchi F,Messerini L,Valanzano R,Smith MC,Cortesini C,Tonelli F,Serio M,Maggi M, et al. Quantitative evaluation of somatostatin receptor subtype 2 expression in sporadic colorectal tumor and in the corresponding normal mucosa. Clin Cancer Res 2002; 8: 41927.
  • 27
    Kostenich G,Livnah N,Bonasera TA,Yechezkel T,Salitra Y,Litman P,Kimel S,Orenstein A. Targeting small-cell lung cancer with novel fluorescent analogs of somatostatin. Lung Cancer 2005; 50: 31928.
  • 28
    Moshitch-Moshkovitz S,Tsarfaty G,Kaufman DW,Stein GY,Shichrur K,Solomon E,Sigler RH,Resau JH,Vande Woude GY,Tsarfaty I. In vivo direct molecular imaging of early tumorigenesis and malignant progression induced by transgenic expression of GFP-Met. Neoplasia 2006; 8: 35363.
  • 29
    Buscail L,Saint-Laurent N,Chastre E,Vaillant JC,Gespach C,Capella G,Kalthoff H,Lluis F,Vaysse N,Susini C. Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer. Cancer Res 1996; 56: 18237.
  • 30
    Pinzani P,Orlando C,Raggi CC,Distante V,Valanzano R,Tricarico C,Maggi M,Serio M,Pazzagli M. Type-2 somatostatin receptor mRNA levels in breast and colon cancer determined by a quantitative RT-PCR assay based on dual label fluorogenic probe and the TaqMan technology. Regul Pept 2001; 99: 7986.
  • 31
    Smitha MC,Maggi M,Orlando C. Somatostatin receptors in non-endocrine tumours. Dig Liver Dis 2004; 36 ( Suppl 1): S78S85.
  • 32
    Hamada Y,Oishi A,Shoji T,Takada H,Yamamura M,Hioki K,Yamamoto M. Endocrine cells and prognosis in patients with colorectal carcinoma. Cancer 1992; 69: 26416.
  • 33
    de Bruine AP,Wiggers T,Beek C,Volovics A,von Meyenfeldt M,Arends JW,Bosman FT. Endocrine cells in colorectal adenocarcinomas: incidence, hormone profile and prognostic relevance. Int J Cancer 1993; 54: 76571.
  • 34
    Achilefu S,Jimenez HN,Dorshow RB,Bugaj JE,Webb EG,Wilhelm RR,Rajagopalan R,Johler J,Erion JL. Synthesis, in vitro receptor binding, and in vivo evaluation of fluorescein and carbocyanine peptide-based optical contrast agents. J Med Chem 2002; 45: 200315.
  • 35
    Stahl A,Meisetschläger G,Schottelius M,Bruus-Jensen K,Wolf I,Scheidhauer K,Schwaiger M. [123I]Mtr-TOCA, a radioiodinated and carbohydrated analogue of octreotide: scintigraphic comparison with [111In]octreotide. Eur J Nucl Med Mol Imag 2006; 33: 4552.
  • 36
    Watson JC,Balster DA,Gebhardt BM,O'Dorisio TM,O'Dorisio MS,Espenan GD,Drouant GJ,Woltering EA. Growing vascular endothelial cells express somatostatin subtype 2 receptors. Br J Cancer 2001; 85: 26672.
  • 37
    Hennig IM,Laissue JA,Horisberger U,Reubi JC. Substance-P receptors in human primary neoplasms: tumoral and vascular localization. Int J Cancer 1995; 61: 78692.
  • 38
    Reubi JC,Horisberger U,Laissue J. High density of somatostatin receptors in veins surrounding human cancer tissue: role in tumor-host interaction? Int J Cancer 1994; 56: 6818.
  • 39
    Denzler B,Reubi JC. Expression of somatostatin receptors in peritumoral veins of human tumors. Cancer 1999; 85: 18898.
  • 40
    Fjallskog ML,Ludvigsen E,Stridsberg M,Oberg K,Eriksson B,Janson ET. Expression of somatostatin receptor subtypes 1 to 5 in tumor tissue and intratumoral vessels in malignant endocrine pancreatic tumors. Med Oncol 2003; 20: 5967.
  • 41
    Szepeshazi K,Schally AV,Halmos G,Armatis P,Hebert F,Sun B,Feil A,Kiaris H,Nagy A. Targeted cytotoxic somatostatin analogue AN-238 inhibits somatostatin receptor-positive experimental colon cancers independently of their p53 status. Cancer Res 2002; 62: 7818.
  • 42
    Tejeda M,Gaal D,Barna K,Csuka O,Keri G. The antitumor activity of the somatostatin structural derivative (TT-232) on different human tumor xenografts. Anticancer Res 2003; 23: 40616.
  • 43
    Szegedi Z,Takacs J,Szende B,Vadasz Z,Horvath A,Gulyas E,Toth G,Petak I,Bocsi J,Keri G. A specifically radiolabeled somatostatin analog with strong antitumor activity induces apoptosis and accumulates in the cytosol and the nucleus of HT29 human colon carcinoma cells. Endocrine 1999; 10: 2534.
  • 44
    Buscail L,Delesque N,Esteve JP,Saint-Laurent N,Prats H,Clerc P,Robberecht P,Bell GI,Liebow C,Schally AV,Vaysse N,Susini C. Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2. Proc Natl Acad Sci USA 1994; 91: 231519.
  • 45
    Siehler S,Seuwen K,Hoyer D. [125I][Tyr3]octreotide labels human somatostatin sst2 and sst5 receptors. Eur J Pharmacol 1998; 348: 31120.
  • 46
    Bruns C,Lewis I,Briner U,Meno-Tetang G,Weckbecker G. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 2002; 146: 70716.
  • 47
    Feuerbach D,Fehlmann D,Nunn C,Siehler S,Langenegger D,Bouhelal R,Seuwen K,Hoyer D. Cloning, expression and pharmacological characterisation of the mouse somatostatin sst(5) receptor. Neuropharmacology 2000; 39: 145162.
  • 48
    Wali RK,Roy HK,Kim YL,Liu Y,Koetsier JL,Kunte DP,Goldberg MJ,Turzhitsky V,Backman V. Increased microvascular blood content is an early event in colon carcinogenesis. Gut 2005; 54: 65460.
  • 49
    Raggi CC,Cianchi F,Valanzano R,Smith MC,Serio M,Maggi M,Orlando C. Prognostic value of somatostatin receptor subtype 2 expression in colorectal cancer. Regul Pept 2005; 132: 236.